This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
As one of many clinicians who has had gratifying and often dramatic results with iproniazid in the treatment of depressions and melancholia, I welcomed the editorial concerning this drug in The Journal (168:50 [Sept. 6] 1958). I wish to comment on two points discussed in the editorial—dosage in relation to toxicity and the risk versus the severity of indication. Concerning the first point, the statement that "because the incidence of toxic manifestations (particularly jaundice) may be dependent on dosage" is not borne out by the evidence. From a thoroughgoing study of the reported incidence of hepatitis and fatalities from hepatonecrosis during iproniazid therapy, it is unfortunately clear that no dosage-toxicity relationship can be demonstrated at the present time. The implication that only in institutionalized patients is adequate supervision possible and a maximal initial dose of 150 mg. warranted is also not in keeping with clinical experience.
Robie TR. TOXICITY OF IPRONIAZID. JAMA. 1958;168(13):1802–1803. doi:10.1001/jama.1958.03000130068018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: